Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Current Assets (2016 - 2025)

Historic Current Assets for Amicus Therapeutics (FOLD) over the last 17 years, with Q3 2025 value amounting to $594.1 million.

  • Amicus Therapeutics' Current Assets rose 1917.69% to $594.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $594.1 million, marking a year-over-year increase of 1917.69%. This contributed to the annual value of $504.7 million for FY2024, which is 448.7% up from last year.
  • Per Amicus Therapeutics' latest filing, its Current Assets stood at $594.1 million for Q3 2025, which was up 1917.69% from $538.0 million recorded in Q2 2025.
  • Amicus Therapeutics' Current Assets' 5-year high stood at $650.5 million during Q3 2021, with a 5-year trough of $399.7 million in Q1 2023.
  • For the 5-year period, Amicus Therapeutics' Current Assets averaged around $497.2 million, with its median value being $497.6 million (2022).
  • As far as peak fluctuations go, Amicus Therapeutics' Current Assets soared by 2516.85% in 2021, and later crashed by 2951.41% in 2022.
  • Over the past 5 years, Amicus Therapeutics' Current Assets (Quarter) stood at $596.8 million in 2021, then decreased by 28.99% to $423.8 million in 2022, then grew by 13.98% to $483.1 million in 2023, then increased by 4.49% to $504.7 million in 2024, then rose by 17.7% to $594.1 million in 2025.
  • Its Current Assets stands at $594.1 million for Q3 2025, versus $538.0 million for Q2 2025 and $510.8 million for Q1 2025.